John Parkinson is a professor and journalist whose work has appeared in various publications and media outlets. He focuses on a wide range of topics, including healthcare, infectious diseases, public health, and international diplomacy. With his expertise and experience, John provides insightful analysis and reporting on important issues that impact society.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
John Parkinson's coverage focuses on healthcare, pharmaceuticals, government announcements and politics with a particular emphasis on infectious diseases such as COVID-19. This suggests that he would be interested in receiving pitches related to the latest developments in medical research, public health initiatives, vaccine analytics and government decisions impacting healthcare.
Given his focus on citing data and evolving stories within the healthcare sector, John may be particularly receptive to pitches that offer exclusive access to new scientific findings or insights into emerging trends related to infectious diseases.
As there is no specified geographic focus for John's articles, it can be assumed that he covers global issues within the field of healthcare and infectious diseases.
This information evolves through artificial intelligence and human feedback. Improve this profile .
In the second part of our conversation, Abdulwhab Shremo Msdi, PharmD, discusses using this methodology.
By: John Parkinson
There are high infection rates in this population, but limited opportunities to bring about awareness and education. However, a newer program sponsored by ViiV Healthcare looks to engage these women and bring about a better understanding behind transmission and care.
The federal agency is asking hospitalists and labs to accelerate this process in order to know if they are dealing with avian influenza.
Robert H. Hopkins, Jr, MD, medical director, National Foundation for Infectious Diseases (NFID) provides an update on incidence rates and virus patterns across different regions of the US.
By: John Parkinson
George Thompson, MD, offers some insights on 2 studies looking at these antifungals in patients with candidemia and invasive candidiasis.
The federal government is working on measures to mitigate the potential impact including looking at vaccines, therapies, and other strategies. Robert Hopkins, Jr, MD, medical director, National Foundation for Infectious Diseases (NFID), provides some insights on our preparation now and lessons learned from the pandemic.
Johnson and Trump say they'll do it in one big bill, Thune doesn't go that far.
In the second interview segment with George Thompson, MD, he provides feedback on patient profiles and prescribing practices for the antifungals.
By: John Parkinson
As a new administration is taking hold, Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, discusses the last administration’s approach to the 2026 Notice of Benefit and Payment Parameters rule and its effects on patient cost-sharing.
By: Hongbo Guo, Irina Rodionova, Hui Peng, Shubham Dutta, Mohamed Taha Moutaoufik, Andrew Emili, Leslie Dan, Neal Kewalramani, Oxana Pogoutse, Sergei Kotelnikov, Shany Ofaim, Hiroyuki Aoki, Grant C. Stevens, John Parkinson, Mikhail Ignatov, Andre
Ligand interaction landscape of transcription factors and essential enzymes in E. coli Hui Peng Hui Peng
(833) 317-6278 
